Enrollment in the cohort of patients with NF1 inoperable plexiform neurofibromas (PN) is temporarily suspended as of Amendment G as requested by the FDA due to IND Safety Report of 07 October 2016. Patient accrual of patients with NF1 and MPNST may continue in the Phase I Portion.